Vivos Therapeutics raises ~$2.1M in PIPE of convertible preferred and warrants

Vivos Therapeutics, Inc.

Sold 3,608,496 units at $0.582/unit; each unit: one Series A Convertible Preferred (stated value $0.456) and one warrant (exercise $0.456, 5-year term).
Gross proceeds ~$2.1M; $1M cash, $1M from conversion of bridge note; net proceeds for working capital.
CEO R. Kirk Huntsman indirectly invested $50k via V-Co 4, an affiliate holding >9.99% of common stock.
Warrants immediately exercisable; beneficial ownership limits: 19.99% for V-Co 4, 9.99% (or 4.99%) for Bigger Capital.
Company must file resale registration statement within 45 days; Rights contingent on SEC effectiveness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.